Subscribe to our mailing list
Since Tri-Solfen® was commercially launched, over 80 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…
‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’
Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.
'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'
Rod Miller– Glenpaen Merino Stud, Horsham, Vic
'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'
Richard Coole– Frankland, W.A.
'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'
Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.
'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'
Kent Lummis– Waverley Downs, Gilgandra, NSW
Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.
Human Wound and Regulatory Advisor
Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.
Medical Specialist Advisor
Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.
Medical Specialist Scientific Director
Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.
Veterinarian Research Advisor
Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.
Global Regulatory Affairs Advisor
Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.
Tri-Solfen® is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improves wound healing. Tri-Solfen® contains two proven topical local anaesthetics; fast-acting Lignocaine for immediate pain relief and long-acting bupivacaine for prolonged post-operative pain relief. Adrenaline is included for its ability to reduce the shock and stress of blood loss, whilst prolonging the anaesthetic action. Tri-Solfen® also contains Cetrimide; an antiseptic widely used to cleanse skin and wounds and provides protection from bacterial contamination.
17 December 2018
The MHRA approves Phase IIa clinical trial application for Tri-Solfen® for venous leg ulcers
24 September 2018
Prestigious grant to help fast-track new pain mitigation delivery via livestock feed supplements
20 August 2018
Medical Ethics appoints leading British Army surgeon to its Advisory Board
26 July 2018
Medical Ethics selects Bayer as New Zealand commercial partner for Tri-Solfen®
9 July 2018
Australian beef and dairy industry welcomes new registrations for Tri-Solfen®
22 May 2018
Australian life sciences company Medical Ethics announce a £3 million investment in Wales
16 November 2017
Tri-Solfen registered in New Zealand for sheep and cattle husbandry procedures
27 September 2017
Zanda’s cattle pain relief vision on show
3 April 2017
Australian Research Company Animal Ethics Secures UK investment partner
15 December 2016
World 1st: Tri-Solfen® approved for use in calves
5 October 2016
Taking the pain out of lamb marking: Tri–Solfen® approved for extended use in all sheep breeds
21 July 2016
Australian Government confirms Tri-Solfen® number 1 registration priority for livestock industries
4 June 2015
Animal pain relief product Tri-Solfen® – US patent granted
19 December 2011
Farm animal pain relief product Tri–Solfen® achieves Australian government registration
3 November 2007
Australian Government Supports Pain Relief Research
7 August 2006
Help for mulesing pain
26 October 2005
“Broad Industry Approval: ‘Tri-Solfen®’ A World First in Pain Relief for Lambs”